Marshall M J, Holt I, Davie M W
Charles Salt Research Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, England.
Calcif Tissue Int. 1993 Jan;52(1):21-5. doi: 10.1007/BF00675622.
Though some evidence suggests that bisphosphonates (BPs) act directly on osteoclasts to inhibit bone resorption, other evidence suggests that they inhibit the development of the osteoclast. We found an increase in osteoclast recruitment in 2-day-old mice given (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). A threefold increase in 5-bromo-2'-deoxyuridine (BrdU)-labeled osteoclast nuclei was observed on mouse parietal bones 3 days after APD injection. This suggests that inhibition of osteoclast development is not an action of APD in mice of this age. The mechanism of the increased recruitment was investigated. As osteoclast progenitors were not detected on parietal bones in vitro, we looked for an increase in circulating monocytes to account for the recruitment. No such increase was found, but when 51Cr-labeled bone marrow was injected intraperitoneally into mice given APD there was an increase in accumulation of 51Cr in calvaria and in femur and tibia over controls. This increase did not occur when 51Cr-labeled erythrocytes or free 51Cr was injected. We conclude that APD causes increased recruitment of osteoclast precursors by increasing the avidity of bone for hematopoietically derived cells.
尽管一些证据表明双膦酸盐(BPs)直接作用于破骨细胞以抑制骨吸收,但其他证据表明它们抑制破骨细胞的发育。我们发现,给2日龄小鼠注射(3-氨基-1-羟基亚丙基)-1,1-双膦酸盐(APD)后,破骨细胞募集增加。注射APD 3天后,在小鼠顶骨上观察到5-溴-2'-脱氧尿苷(BrdU)标记的破骨细胞核增加了两倍。这表明抑制破骨细胞发育不是APD对这个年龄段小鼠的作用。我们研究了募集增加的机制。由于在体外未在顶骨上检测到破骨细胞祖细胞,我们寻找循环单核细胞的增加以解释这种募集。未发现这种增加,但当将51Cr标记的骨髓腹腔注射到给予APD的小鼠中时,与对照组相比,颅骨、股骨和胫骨中51Cr的积累增加。当注射51Cr标记的红细胞或游离51Cr时,这种增加并未发生。我们得出结论,APD通过增加骨对造血来源细胞的亲和力导致破骨细胞前体的募集增加。